Inhaled corticosteroid dose-response on blood eosinophils in asthma
Lipworth, Brian; Jabbal, Sunny; Manoharan, Arvind; Anderson, William; Short, Philip

Published in:
The Lancet Respiratory Medicine

DOI:
10.1016/S2213-2600(15)00504-4

Publication date:
2016

Document Version
Peer reviewed version

Link to publication in Discovery Research Portal

Citation for published version (APA):
Title: Inhaled corticosteroid dose response on blood eosinophils in asthma

Article Type: Correspondence

Corresponding Author: Prof. Brian Lipworth, MD

Corresponding Author's Institution: University of Dundee

First Author: Brian Lipworth, MD

Order of Authors: Brian Lipworth, MD; Sunny Jabbar, MBChB; Arvind Manoharan, MBChB; William Anderson, MBChB; Philip Short, MD

Manuscript Region of Origin: UNITED KINGDOM

© <year>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/

DOI: 10.1016/S2213-2600(15)00504-4
Inhaled corticosteroid dose response on blood eosinophils in asthma

Authors:

Dr Brian Lipworth, MD
Dr Sunny Jabbal, MBChB
Dr Arvind Manoharan, MBChB
Dr William Anderson, MBChB
Dr Philip Short, MD

Scottish Centre for Respiratory Research
Ninewells Hospital and Medical School
University of Dundee, DD1 9SY, Scotland, UK

Correspondence: Brian Lipworth, b.j.lipworth@dundee.ac.uk Tel: +44 (0)1382 383902, Fax +44 (0)1382 383259
To the editor:

We read with interest the article by Price et al.\(^1\) showing a clear association between asthma control and a spot measurement of blood eosinophils. The mean beclometasone equivalent inhaled corticosteroid (ICS) dose in their cohort was 219µg/day. It is important to consider the dose response relationship of ICS dose on blood eosinophils. There is evidence of a dose response effect of ICS on reduction of blood eosinophils and eosinophilic cationic protein (ECP) for beclometasone equivalent ICS doses of up to 800µg/day.\(^2-4\) In terms of mechanism it appears that dose related reduction in blood eosinophils and ECP by ICS is disconnected from commensurate adrenal suppression,\(^3,5\) suggesting that systemic bioavailability of ICS may not be the principal cause of suppressing blood eosinophils.

The data from Price et al.\(^1\) were somewhat conflicting showing that patients on step 4 therapy with high dose ICS had a 13% increased likelihood of having a blood eosinophil count >400 cells/µL, which was not observed for step 3 patients who were also taking ≥ 800µg/day beclometasone equivalent ICS dose, while step 2 patients on low dose ICS were 8% less likely to have a raised count. However we appreciate that it might be difficult to dissect out the suppressive effects of ICS on eosinophils per se from the ICS dose being a proxy for associated asthma severity. Titrating ICS dose over 1 year against mannitol airway hyper-responsiveness,\(^5\) results in reduced exacerbations, improved symptom control and reduced reliever use, accompanied by a 34% fall in ECP. The relative suppression of eosinophils and ECP in response to 400µg/day beclometasone equivalent ICS dose is 23% and 17% respectively for blood and 76% and 55% for sputum,\(^6\) inferring that sputum is more
sensitive, although it is less practical. In this regard it has been shown that titrating ICS against sputum eosinophils results in reduced exacerbations and associated AHR.\textsuperscript{7} It would therefore be relevant to know if using serial blood eosinophils to adjust the ICS dose might result in reduced exacerbations, especially in patients who already have an optimised asthma control questionnaire score \textless 0.75\textsuperscript{8} at the time when the eosinophil count is measured.

Dr Brian Lipworth
Dr Sunny Jabbal
Dr Arvind Manoharan
Dr William Anderson
Dr Philip Short

Scottish Centre for Respiratory Research
Ninewells Hospital and Medical School
University of Dundee, DD1 9SY, Scotland, UK

Correspondence: b.j.lipworth@dundee.ac.uk

References


